chartexchange

IMUC
EOM PHARMACEUTICAL HLDNGS
stockOTC

EODNov 18, 2026
0.1574USD-0.063%(-0.0001)700
Loading…
Loading…
Healthcare
Biotechnology
HQ
Montvale, NJ, USA
Previous Close
$0.16
Beta
-1.76
52-Week High
$0.27 2026-06-09
52-Week Low
$0.02 2026-09-29
SMA 50
$0.16
SMA 200
$0.14
Avg. Vol 10D
2,596
Avg. Vol 30D
3,465
Avg. Vol 90D
6,995
Relative Vol
1.62
113.27M
126.14M
1,369
Sep 16, 2020 · 1-for-10 (reverse)
IMUC Profile

immunocellular therapeutics, ltd. is a los angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. immunocellular has concluded a phase 2 trial of its lead product candidate, ict-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. immunocellular's pipeline also includes: ict-121, a dendritic cell immunotherapy targeting the cd133 antigen on stem cells in recurrent glioblastoma; ict-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the stem-to-t-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing t-cells.

IMUC Performance
PeriodPriceDateChangeBeta
1M0.122026-10-21+30.38%-22.748
3M0.142026-08-18+12.50%-7.969
6M0.122026-05-15+36.96%-3.634
1Y0.182025-11-18-12.01%-1.760
2Y0.202024-11-18-21.25%—
5Y0.562021-11-18-71.88%0.253
IMUC Stock Summary

EOM PHARMACEUTICAL HLDNGS (OTC:IMUC) stock price today is $0.16, and today's volume is 5,601. IMUC is down 0.190% today. The 30 day average volume is 3,465. IMUC market cap is $17.84M with 113.27M shares outstanding.